In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xellia Pharmaceuticals AS

Latest From Xellia Pharmaceuticals AS

Civica Rx Supplies First Drug In US

A US hospital has received shipment of the first drug to be provided under the affordable generic supply scheme launched by Civica Rx, a nationwide coalition of hospital healthcare groups dedicated to reducing medicine shortages and tackling high prices.

Strategy United States

People Round-Up: Dipharma And Xellia North America Get New Heads

Dipharma appoints a new CEO, Xellia gets a new commercial head in North America, promotions are made at Lek, GVK Bio and the APhA, while appointments are seen at Auris Medical and Tris Pharma.

Appointments Strategy

Hikma Strikes Deal To Supply 14 To Civica Rx

Hikma has struck a five-year deal with US firm Civica Rx through which it will supply 14 essential medicines to the operation aimed at tackling shortages in the US.

Deals Generic Drugs

Manufacturing Round-Up: Sterling Completes Expansion As Xellia Teams With Civica Rx

Sterling Pharma Solutions completes an expansion of its UK pilot plant facility, Aphena invests, Dr Reddy’s and Asymchem get nods from the FDA, Ampersand Capital Partners acquires Germany’s Vibalogics, and Xellia strikes a deal with Civica Rx.

Manufacturing Compliance
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Norway
  • Parent & Subsidiaries
  • Xellia Pharmaceuticals AS
  • Senior Management
  • Carl-Åke Carlsson, Pres. & CEO
    Kennet Lundberg, VP, CFO
    Gaël Bernard, VP, Sales & Mktg.
    Aleksandar Danilovski, VP, R&D
  • Contact Info
  • Xellia Pharmaceuticals AS
    Phone: 22 52 90 00
    Harbitzalléen 3
    P.O. Box 158 Oslo, 0212